NCT06778278 Transition Health and Resilience Through Valued Experiences (THRiVE) Pilot for Newly Separated Veterans
| NCT ID | NCT06778278 |
| Status | Recruiting |
| Phase | — |
| Sponsor | RTI International |
| Condition | Military Transition |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2025-07-30 |
| Primary Completion | 2026-10-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2025-07-30 with a primary completion date of 2026-10-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The objective of this study is to develop and pilot a program designed to improve mental health outcomes and reduce suicide risk during the transition from military to civilian life. It is hypothesized that the Transition Health and Resilience through Valued Experiences (THRiVE) program, to be developed as part of this study, will meet participant recruitment, retention, and satisfaction benchmarks (primary outcomes) and show positive preliminary effects on mental health symptoms, risk factors for suicidal ideation, and psychosocial functioning outcomes (secondary outcomes). The specific aims of this study are to: 1. Develop a small-group, peer-led, cross-cutting prevention program for newly separated veterans (NSVs) called THRiVE and 2. Evaluate the feasibility, acceptability, and preliminary effects of the THRiVE program on mental health symptoms, risk factors for suicidal ideation, and psychosocial functioning outcomes. Up to 40 NSVs participating in this Stage 1 pilot study will complete validated self-report measures at baseline, immediately after completing the THRiVE program (post-THRiVE), and 3 months after completing the THRiVE program (follow-up). The duration of a participant's time in the study is anticipated to be 5 months.
Eligibility Criteria
Inclusion Criteria: * Be either (a) a United States military veteran who separated no more than 12 months prior to study enrollment or (b) a United States transitioning service member on terminal leave * Be at least 18 years old * Have access to the internet; a desktop computer, laptop, tablet, or other "smart" device with video camera, speakers, and microphone; and a private place from which to attend THRiVE sessions * Reside and complete all study activities within the United States Exclusion Criteria: * Endorse lifetime manic, hypomanic, or psychotic episodes * Meet Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria for current severe alcohol use disorder or substance use disorder (except for tobacco use disorder, which will not be exclusionary) * Screen positive for moderate or high acute risk for suicide * Screen positive for more than minimal risk for other-directed violence * Are receiving or plan to receive BA therapy for any mental health condition between enrollment and the 3-month follow-up assessment
Contact & Investigator
Shannon M Blakey, PhD
PRINCIPAL INVESTIGATOR
RTI International
Frequently Asked Questions
Who can join the NCT06778278 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Military Transition. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06778278 currently recruiting?
Yes, NCT06778278 is actively recruiting participants. Contact the research team at sblakey@rti.org for enrollment information.
Where is the NCT06778278 trial being conducted?
This trial is being conducted at Durham, United States.
Who is sponsoring the NCT06778278 clinical trial?
NCT06778278 is sponsored by RTI International. The principal investigator is Shannon M Blakey, PhD at RTI International. The trial plans to enroll 40 participants.